Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptomatic Aortic Stenosis Clear all
Active, not recruiting Not applicable Interventional

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

NCT05712161
View directory record Official record
Conditions
Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification
Interventions
DurAVRTM THV System
Device
Lead sponsor
Anteris Technologies Ltd.
Industry
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
5
States / cities
Tucson, Arizona • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B

NCT02184442
View directory record Official record
Conditions
Severe, Symptomatic, Calcific Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, TAVR Implantation with SAPIEN
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
53
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 3, 2026, 11:00 AM EDT
Not listed Not applicable Interventional Results available

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

NCT02732691
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
Interventions
JenaValve Pericardial TAVR System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial

NCT00530894
View directory record Official record
Conditions
Critical Aortic Stenosis
Interventions
Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty
Device · Other
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 3, 2026, 11:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed No phase listed Observational Results available

Optimize PRO Study

NCT04091048
View directory record Official record
Conditions
Symptomatic Aortic Stenosis
Interventions
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
37
States / cities
Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Active, not recruiting Not applicable Interventional Results available

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

NCT04722250
View directory record Official record
Conditions
Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Interventions
Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems, Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
61
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Recruiting Not applicable Interventional

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

NCT07278310
View directory record Official record
Conditions
Symptomatic Severe Native Aortic Stenosis, Aortic Stenosis
Interventions
TAVR Device, Siegel TAVR Device
Device
Lead sponsor
MiRus
Industry
Eligibility
18 Years and older
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7

NCT03222141
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR Implantation of the THV Prosthesis
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Active, not recruiting Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 2Phase 3 Interventional

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

NCT03723655
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
31
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 3, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

NCT01737528
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
The Society of Thoracic Surgeons
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 3, 2026, 11:00 AM EDT
Active, not recruiting Not applicable Interventional

Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

NCT06680427
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)
Device
Lead sponsor
MiRus
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 3, 2026, 11:00 AM EDT
Withdrawn No phase listed Observational

Assessment of Neurologic Injury Subsequent to Transcatheter Aortic Valve Replacement: A Feasibility Study

NCT01927601
View directory record Official record
Conditions
Severe Symptomatic Aortic Stenosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

NCT01240902
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 3, 2026, 11:00 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Enrolling by invitation Not applicable Interventional

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Interventions
Navitor Transcatheter Aortic Valve Implantation (TAVI) System, Any Commercially Available Transcatheter Aortic Valve (CAV) System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate

NCT03222128
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
51
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 3, 2026, 11:00 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

NCT05582395
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Recruiting Not applicable Interventional

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240
View directory record Official record
Conditions
Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 3, 2026, 11:00 AM EDT